References
- Timmer C J, Mulders T M. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet 2000; 39: 233–242
- van den Heuvel M, van Bragt A, Alnabawy A, et al. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 2005; 72: 168–174
- Roumen F J, Apter D, Mulders T M, et al. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod 2001; 16: 469–475
- Oddsson K, Leifels-Fischer B, de Melo N R, et al. Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: A 1-year randomized trial. Contraception 2005; 72: 176–182
- Ahrendt H -J, Nisand I, Bastianelli C, et al. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 µg of ethinyl estradiol and 3 mg of drospirenone. Contraception 2006; 74: 451–457
- Bjarnadóttir R I, Tuppurainen M, Killick S R. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol. Am J Obstet Gynecol 2002; 186: 389–395
- Oddsson K, Leifels-Fischer B, Wiel-Masson D, et al. Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 (micro)g ethinylestradiol and 150 (micro)g levonorgestrel: a randomized trial. Hum Reprod 2005; 20: 557–562
- Milsom I, Lete I, Bjertnaes A, et al. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 (micro)g ethinyl estradiol and 3 mg drospirenone. Hum Reprod 2006; 21: 2304–2311
- Rosenberg M J, Waugh M S. Oral contraceptive discontinuation: A prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1988; 179: 577–582
- Gallo M F, Nanda K, Grimes D A, et al. 20 mcg versus >20 mcg Estrogen combined oral contraceptives for contraception. The Cochrane Database of Systematic Reviews 2006, 1
- Novák A, de la Loge C, Abetz L, et al. The combined contraceptive vaginal ring, NuvaRing: An international study of user acceptability. Contraception 2003; 67: 187–194
- Rosenberg M J, Burnhill M S, Waugh M S, et al. Compliance and oral contraceptives: A review. Contraception 1995; 52: 137–141
- Benedetto C, Lounsbach G. European women's survey on oral contraceptive use. Eur J Contracept Reprod Health Care 2004; 9(Suppl 1)77
- Nap M, Apter D, Tuomivaara L. Acceptability of NuvaRing in young women. Eur J Contracept Reprod Health Care 2004; 9(Suppl 1)176
- Roumen F J, op ten Berg M M, Hoomans E H. The combined contraceptive vaginal ring (NuvaRing): First experience in daily clinical practice in The Netherlands. Eur J Contracept Reprod Health Care 2006; 11: 14–22
- Rosenberg M J, Waugh M S, Meehan T E. Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. Contraception 1995; 51: 283–288